Experienced in Autoimmune Hemolytic Anemia

Dr. Zdenka E. Segota

Brrh Oncology, LLC
Boca Raton, FL
Experienced
in Autoimmune Hemolytic Anemia
Specialties:Hematology Oncology | Hematology | Oncology
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Zdenka Segota is a Hematologist Oncology specialist and a Hematologist in Boca Raton, Florida. Dr. Segota and is rated as an Experienced provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. Her top areas of expertise are Inflammatory Breast Cancer, Breast Cancer, Paget Disease of the Breast, and Angiosarcoma. Dr. Segota is currently accepting new patients.

Her clinical research consists of co-authoring 2 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in ME
Hospital Affiliations
Boca Raton Regional Hospital
Delray Medical Center
Holy Cross Hospital
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Anthem
  •  Health Options
  •  Oscar
  •  Humana
  •  Florida Blue

Locations

BRRH ONCOLOGY, LLC
701 Northwest 13th St, 2nd Floor, Boca Raton, FL 33486
561-955-6400

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Drug
Study Drug: Avelumab
Study Phase: Phase 3
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2024
Intervention Type: Drug, Other
Study Drug: Ribociclib
Study Phase: Phase 3
An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid Tumors
An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: October 15, 2024
Intervention Type: Drug, Radiation
Study Phase: Phase 1
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
Enrollment Status: Completed
Publish Date: October 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women
A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women
Enrollment Status: Completed
Publish Date: December 09, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Enrollment Status: Terminated
Publish Date: November 18, 2020
Intervention Type: Drug
Study Phase: Phase 2
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2: A Prospective, Multicenter, Observational Study Examining the Clinical Utility of CANscriptTM in Routine Clinical Practice
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2: A Prospective, Multicenter, Observational Study Examining the Clinical Utility of CANscriptTM in Routine Clinical Practice
Enrollment Status: Suspended
Publish Date: April 08, 2019
Intervention Type: Diagnostic test
View 7 Less Clinical Trials

2 Total Publications

Unusual Brain Lesions Diagnosed From a Cerebrospinal Fluid Wet Preparation in a Patient With AIDS.
Unusual Brain Lesions Diagnosed From a Cerebrospinal Fluid Wet Preparation in a Patient With AIDS.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: May 24, 2020
Similar Doctors
Expertise in
70
conditions
Dr. Howard A. Adler
Oncology | Hematology
Expertise in
70
conditions
Dr. Howard A. Adler
Oncology | Hematology

Brrh Oncology, LLC

701 Northwest 13th St, 2nd Floor, 
Boca Raton, FL 
561-955-6400
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Howard Adler is an Oncologist and a Hematologist in Boca Raton, Florida. Dr. Adler and is rated as a Distinguished provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Non-Hodgkin Lymphoma, Adult Immune Thrombocytopenia, Immune Thrombocytopenic Purpura (ITP), and Anemia. Dr. Adler is currently accepting new patients.

Expertise in
48
conditions
Dr. Lisa D. Reale
Hematology Oncology | Hematology | Oncology
Expertise in
48
conditions
Dr. Lisa D. Reale
Hematology Oncology | Hematology | Oncology

Baptist Health Medical Group Oncology LLC

8900 N Kendall Dr, 
Miami, FL 
 (49.2 mi)
786-596-2000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Lisa Reale is a Hematologist Oncology specialist and a Hematologist in Miami, Florida. Dr. Reale and is rated as a Distinguished provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. Her top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Aspiration. Dr. Reale is currently accepting new patients.

Expertise in
4
conditions
Dr. Eloy A. Roman
Hematology Oncology | Hematology | Oncology
Expertise in
4
conditions
Dr. Eloy A. Roman
Hematology Oncology | Hematology | Oncology
5801 Nw 151 St, Suite 300, 
Miami Lakes, FL 
 (34.1 mi)
305-828-1333
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Eloy Roman is a Hematologist Oncology specialist and a Hematologist in Miami Lakes, Florida. Dr. Roman and is rated as an Advanced provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Autoimmune Hemolytic Anemia, Anemia, Hemolysis, and Hemolytic Anemia. Dr. Roman is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile